


USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No.		Serial No.	
				11111/2002		10/645,000	
INFORMATION DISCLOSURE STATEMENT 				Applicant(s): Segal, et al.			
				Filing Date: August 20, 2003		Group: Not Yet Assigned	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
/BB/	1.	Faulkner, L. et al., (2001), "IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells", <i>International Immunology</i> , 13(6):713-721					
	2.	Batova, A. et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ", <i>Clinical Cancer Research</i> , 5:4259-4263.					
	3.	Frankel, A. et al., (1995), "IL2-Ricin Fusion Toxin Is Selectively Cytotoxic <i>in Vitro</i> to IL2 Receptor-Bearing Tumor Cells", <i>Bioconjugate Chem.</i> , 6:666-672.					
	4.	Gillies, S.D. et al., (1992), "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1428-1432.					
	5.	Barker, E. et al., (1991), "Effect of a Chimeric Anti-Ganglioside G _{D2} Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells", <i>Cancer Research</i> , 51:144-149.					
/BB/	6.	Gillies, S.D. et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody" <i>Hybridoma</i> , 10(3):347-356.					
EXAMINER /Benjamin Blumel/				DATE CONSIDERED 06/04/2007			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>							
<small>**Copies of references not provided at the time of this submission.</small>							



U.S. Patent and Trademark Office
U.S. Department of Commerce

INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

11111/2002

Serial No.

10/645,000

Applicant(s): Segal, et al.

Filing Date: August 20, 2003

Group: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

/BB/	1.	Deliyannis, G. et al., (2000), "A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge", PNAS, 97(12):6676-6680.
------	----	--

EXAMINER /Benjamin Blumel/

DATE CONSIDERED 06/04/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.